Targeting recombinant tissue-type plasminogen activator in acute ischemic stroke based on risk of intracranial hemorrhage or poor functional outcome: An analysis of the third international stroke trial

Stroke

Volumn 45, Issue 4, 2014, Pages 1000-1006

  Whiteley, William N ^a   Thompson, Douglas ^a   Murray, Gordon ^a   Cohen, Geoff ^a   Lindley, Richard I ^b   Wardlaw, Joanna ^a   Sandercock, Peter ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Prognosis; Randomized controlled trial; Stroke; Thrombolytic therapy

Indexed keywords

ALTEPLASE;

AGED; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CALIBRATION; CONTROLLED STUDY; DRUG TARGETING; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); NATIONAL INSTITUTES OF HEALTH STROKE SCALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; RISK REDUCTION; SYMPTOMATIC INTRACRANIAL HEMORRHAGE; SYSTEMATIC REVIEW (TOPIC); VERY ELDERLY;

PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; STROKE; THROMBOLYTIC THERAPY;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INTRACRANIAL HEMORRHAGES; LOGISTIC MODELS; MALE; PREDICTIVE VALUE OF TESTS; RECOMBINANT PROTEINS; RECOVERY OF FUNCTION; RISK FACTORS; ROC CURVE; STROKE; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 84897456076     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.113.004362     Document Type: Article

References (11)

1. Wardlaw JM, Murray V, Berge E, del Zoppo G, Sandercock P, Lindley RL, et al. Recombinant tissue plasminogen activator for acute ischaemic stroke: An updated systematic review and meta-Analysis. Lancet. 2012;379:2364-2372.
2. Strbian D, Sairanen T, Meretoja A, Pitkäniemi J, Putaala J, Salonen O, et al Helsinki Stroke Thrombolysis Registry Group. Patient outcomes from symptomatic intracerebral hemorrhage after stroke thrombolysis. Neurology. 2011;77:341-348.
3. Brown DL, Barsan WG, Lisabeth LD, Gallery ME, Morgenstern LB. Survey of emergency physicians about recombinant tissue plasminogen activator for acute ischemic stroke. Ann Emerg Med. 2005;46:56-60.
4. Sandercock P, Lindley R, Wardlaw J, Dennis M, Innes K, Cohen G, et al; IST-3 Collaborative Group. Update on the third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke and baseline features of the 3035 patients recruited. Trials. 2011;12:252.
5. IST-3 Collaborative Group. Statistical analysis plan for the third International Stroke Trial (IST-3); part of a 'thread' of reports of the trial. Int J Stroke. 2012;7:186-187.
6. IST-3 Collaborative Group. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): A randomised controlled trial. Lancet. 2012;379:2352-2363.
7. Whiteley WN, Slot KB, Fernandes P, Sandercock P, Wardlaw J. Risk factors for intracranial hemorrhage in acute ischemic stroke patients treated with recombinant tissue plasminogen activator: A systematic review and meta-Analysis of 55 studies. Stroke. 2012;43:2904-2909.
8. König IR, Ziegler A, Bluhmki E, Hacke W, Bath PM, Sacco RL, et al Virtual International Stroke Trials Archive (VISTA) Investigators. Predicting long-Term outcome after acute ischemic stroke: A simple index works in patients from controlled clinical trials. Stroke. 2008;39:1821-1826.
9. Wahlgren N, Ahmed N, Dávalos A, Ford GA, Grond M, Hacke W, et al SITS-MOST Investigators. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): An observational study. Lancet. 2007;369:275-282.
10. Frank B, Grotta JC, Alexandrov AV, Bluhmki E, Lyden P, Meretoja A, et al. Thrombolysis in stroke despite contraindications or warnings? Stroke. 2013;44:727-733.
11. IST-3 Collaborative Group. Effect of thrombolysis with alteplase within 6 h of acute ischaemic stroke on long-Term outcomes (the Third International Stroke Trial [IST-3]): 18-month follow-up of a randomised controlled trial. Lancet Neurol. 2013;12:768-776.